Abstract:BackgroundExtremely premature (birth weight < 1250 g) infants are at high risk for acquiring late-onset sepsis and necrotizing enterocolitis, which are associated with significant mortality and morbidity. Own mother's milk contains protective (immune and trophic) biofactors which provide antimicrobial, anti-inflammatory, antioxidant, and immunomodulatory functions, enhance intestinal microbiota, and promote intestinal maturation. Many of these biofactors are most highly concentrated in the milk expressed by mothers of extremely premature infants. However, since extremely premature infants do not receive oral milk feeds until 32 weeks post-conceptional age, they lack the potential benefit provided by milk (biofactor) exposure to oropharyngeal immunocompetent cells, and this deficiency could contribute to late-onset sepsis and necrotizing enterocolitis. Therefore, oropharyngeal administration of own mother's milk may improve the health outcomes of these infants.ObjectivesTo compare the effects of oropharyngeal administration of mother’s milk to a placebo, for important clinical outcomes, including (1A) reducing the incidence of late-onset sepsis (primary outcome) and (1B) necrotizing enterocolitis and death (secondary outcomes). To identify the biomechanisms responsible for the beneficial effects of oropharyngeal mother’s milk for extremely premature infants, including; (2A) enhancement of gastrointestinal (fecal) microbiota (2B) improvement in antioxidant defense maturation or reduction of pro-oxidant status, and (2C) maturation of immunostimulatory effects as measured by changes in urinary lactoferrin.Methods/DesignA 5-year, multi-center, double-blind, randomized controlled trial designed to evaluate the safety and efficacy of oropharyngeal mother’s milk to reduce the incidence of (1A) late-onset sepsis and (1B) necrotizing enterocolitis and death in a large cohort of extremely premature infants (n = 622; total patients enrolled). Enrolled infants are randomly assigned to one of 2 groups: Group A infants receive 0.2 mL of own mother's milk, via oropharyngeal administration, every 2 hours for 48 hours, then every 3 hours until 32 weeks corrected-gestational age. Group B infants receive a placebo (0.2 mL sterile water) following the same protocol. Milk, urine, oral mucosal swab, and stool samples are collected at various time points, before, during and after the treatment periods. Health outcome and safety data are collected throughout the infant’s stay.Trial registrationClinicalTrials.gov identifier: NCT02116699 on 11 April 2014. Last updated: 26 May 2015

Implementing a colostrum-kit reduces the time to first colostrum for neonates admitted to the NICU – a retrospective observational study

Early administration of oropharyngeal colostrum to extremely low birth weight infants.

Study on improving collection feeding safety and quality of colostrum for very (extremely) low birth weight infants

Early provision of oropharyngeal colostrum leads to sustained breast milk feedings in preterm infants

Oropharyngeal Colostrum Administration in Extremely Premature Infants: An RCT

Colostrum oropharyngeal immunotherapy for very low birth weight preterm infants: protocol of an intervention study

Study on safety and feasibility of colostrum oropharyngeal administration for very low birth weight infants

A pilot study to determine the safety and feasibility of oropharyngeal administration of own mother's colostrum to extremely low-birth-weight infants

Effect of Early Administration of Oropharyngeal Colostrum in Reducing Late Onset Neonatal Sepsis

The Effect of Oral Colostrum Application on the Condition of the Mouth and Incidence of Late-Onset Sepsis Among Premature Infants: A Randomized Controlled Trial

Enhancement of immune response mediated by oropharyngeal colostrum administration in preterm neonates

The Effects of Early Oropharyngeal Administration of Microdosed Colostrum on Feeding Status in Ventilated Extremely Low-Birth-Weight Infants

Oropharyngeal Colostrum Administration in Very Low Birth Weight Infants: A Randomized Controlled Trial.

The Effect of Colostrum Supplementation during the First 5 Days of Life on Calf Health, Enteric Pathogen Shedding, and Immunological Response

Effect of Oropharyngeal Administration of Colostrum in Premature Newborns ≤32 Weeks of Gestation on the Immune Response and Neonatal Morbidity: A Double-Blind Randomized Clinical Trial

Oropharyngeal Colostrum Positively Modulates the Inflammatory Response in Preterm Neonates

A Staff Educational Intervention to Increase the Time of Skin-to-Skin Care in a Swedish NICU: A Quality Improvement Project

Clinical adaptation and the state of innate and humoral im- munity of premature infants with extremely low body weight who received oropharyngeal administration of colostrum

Administration colostrum in preventing mortality and morbidity in preterm infants

Anti-Inflammatory and Anti-Allergic Properties of Colostrum from Mothers of Full-Term and Preterm Babies: The Importance of Maternal Lactation in the First Days

Oropharyngeal administration of mother’s colostrum, health outcomes of premature infants: study protocol for a randomized controlled trial